{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:47Z","timestamp":1794565547326,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100279","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:53:28Z","timestamp":1774486408000},"page":"100279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studies"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-6528","authenticated-orcid":false,"given":"Eman","family":"El-Khateeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-734X","authenticated-orcid":false,"given":"Oliver","family":"Hatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udoamaka","family":"Ezuruike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6754","authenticated-orcid":false,"given":"Felix","family":"Stader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib1","first-page":"229","article-title":"Global Cancer Statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.dmd.2026.100279_bib2","first-page":"87","article-title":"Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.dmd.2026.100279_bib3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00228-018-2513-6","article-title":"Utility of physiologically based pharmacokinetic (Pbpk) modeling in oncology drug development and its accuracy: a systematic review","volume":"74","author":"Saeheng","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100279_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","article-title":"The role of human cytochrome P450 Enzymes in the metabolism of anticancer agents: implications for drug interactions","volume":"40","author":"Kivisto","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100279_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1093722","article-title":"Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis","volume":"5","author":"Lippitz","year":"2016","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.dmd.2026.100279_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cpt.3560","article-title":"Cytokine dynamics in action: a mechanistic approach to assess interleukin 6 related therapeutic protein-drug-disease interactions","volume":"117","author":"Pan","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100279_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cpt.917","article-title":"Harnessing meta-analysis to refine an oncology patient population for physiology-based pharmacokinetic modeling of drugs","volume":"103","author":"Schwenger","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100279_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpt.128","article-title":"Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window","volume":"98","author":"Coutant","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/cpt.2633","article-title":"Quantitative proteomics of hepatic drug-metabolizing enzymes and transporters in patients with colorectal cancer metastasis","volume":"112","author":"Vasilogianni","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (Pbpk) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2026.100279_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105355","article-title":"A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients","volume":"150","author":"Mendes","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cpt.3506","article-title":"Clinical and physiologically based pharmacokinetic model evaluations of adagrasib drug-drug interactions","volume":"117","author":"Cilliers","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100279_bib15","series-title":"Statistical Inference Via Data Science: A Moderndive into R and the Tidyverse","article-title":"Chapter 8: Bootstrapping and Confidence Intervals","author":"Ismay","year":"2020"},{"issue":"7","key":"10.1016\/j.dmd.2026.100279_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/dmd.121.000359","article-title":"Hepatic scaling factors for in vitro-in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis","volume":"49","author":"Vasilogianni","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100279_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1148\/radiol.2242011322","article-title":"Hepatic metastases in patients with colorectal cancer: relationship between size of metastases, standard of reference, and detection rates","volume":"224","author":"van Erkel","year":"2002","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/bcp.15544","article-title":"Effect of capmatinib on the pharmacokinetics of substrates of Cyp3a (midazolam) and Cyp1a2 (caffeine) in patients with Met-dysregulated solid tumours","volume":"89","author":"Chen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100279_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-012-2001-0","article-title":"Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer","volume":"71","author":"Chi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100279_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.2010.158","article-title":"An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors","volume":"88","author":"Goh","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2026.100279_bib22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jcph.510","article-title":"Pharmacokinetic (Pk) drug interaction studies of cabozantinib: effect of Cyp3a inducer rifampin and inhibitor ketoconazole on cabozantinib plasma Pk and effect of cabozantinib on Cyp2c8 probe substrate rosiglitazone plasma Pk","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100279_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-012-1996-6","article-title":"Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential","volume":"71","author":"LoRusso","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100279_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmd.2026.100279_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5414\/CPP46365","article-title":"Cytochrome P450 2c9 mediated metabolism in people with and without cancer","volume":"46","author":"Shord","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcph.1734","article-title":"Evaluation of potential drug-drug interaction risk of pexidartinib with substrates of cytochrome P450 and P-glycoprotein","volume":"61","author":"Zahir","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100279_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00280-015-2934-1","article-title":"A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin","volume":"77","author":"Agarwal","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"10.1016\/j.dmd.2026.100279_bib28","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1200\/JCO.2005.09.129","article-title":"Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer","volume":"23","author":"Camidge","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3A","key":"10.1016\/j.dmd.2026.100279_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/00000542-198809010-00602","article-title":"Effects of increased alpha-1-acid glycoprotein in cancer patients on pharmacokinetics of alfentanil [Abstract]","volume":"69","author":"Meistelman","year":"1988","journal-title":"Anesthesiology"},{"issue":"20","key":"10.1016\/j.dmd.2026.100279_bib30","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","article-title":"Effect of common Cyp3a4 and Cyp3a5 variants on the pharmacokinetics of the cytochrome P450 3a phenotyping probe midazolam in cancer patients","volume":"11","author":"Lepper","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100279_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jcph.2362","article-title":"Is higher docetaxel clearance in prostate cancer patients explained by higher Cyp3a? An in vivo phenotyping study with midazolam","volume":"64","author":"van der Heijden","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.dmd.2026.100279_bib32","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","article-title":"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of Pf-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors","volume":"30","author":"Infante","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100279_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.434","article-title":"Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of Cyp3a substrate midazolam","volume":"55","author":"Zhang","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100279_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00280-010-1426-6","article-title":"Nct01110291: induction of Cyp3a activity and lowered exposure to docetaxel in patients with primary breast cancer","volume":"67","author":"Hilli","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100279_bib37","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (Sti571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3a4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.dmd.2026.100279_bib38","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1111\/bcp.13753","article-title":"Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin","volume":"84","author":"Harvey","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"10.1016\/j.dmd.2026.100279_bib39","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/Ib dose-finding study of adagrasib (Mrtx849) in patients with advanced Kras(G12c) solid tumors (Krystal-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100279_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-015-2708-9","article-title":"The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia","volume":"75","author":"de Jong","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100279_bib42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00280-011-1635-7","article-title":"Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer","volume":"68","author":"Tsimberidou","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100279_bib43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00280-013-2237-3","article-title":"A clinical investigation of inhibitory effect of panobinostat on Cyp2d6 substrate in patients with advanced cancer","volume":"72","author":"Feld","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100279_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100279_bib45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-010-1367-0","article-title":"Marginal increase of sunitinib exposure by grapefruit juice","volume":"67","author":"van Erp","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100279_bib46","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1111\/bcp.14822","article-title":"Food constituent- and herb-drug interactions in oncology: influence of quantitative modelling on drug labelling","volume":"87","author":"Pilla Reddy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100279_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00228-025-03839-1","article-title":"A novel physiologically-based pharmacokinetic model to estimate reduced Cyp3a4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker","volume":"81","author":"Coutant","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100279_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jss.2020.09.039","article-title":"Size of the largest colorectal liver metastasis is an independent prognostic factor in the neoadjuvant setting","volume":"259","author":"Ren","year":"2021","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.dmd.2026.100279_bib50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.dmd.2026.100279_bib51","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1096\/fj.02-0195fje","article-title":"Down-regulation of human Cyp3a4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved","volume":"16","author":"Jover","year":"2002","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.dmd.2026.100279_bib52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/genes11121509","article-title":"Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics","volume":"11","author":"de Jong","year":"2020","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.dmd.2026.100279_bib53","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome P450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2026.100279_bib54","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.xphs.2021.05.008","article-title":"The pharmacokinetics of gefitinib in a chinese cancer population group: a virtual clinical trials population study","volume":"110","author":"He","year":"2021","journal-title":"J Pharm Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:51:23Z","timestamp":1794563483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000486"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100279","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studies","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100279"}}